Day 7 TNFR1 ratio correlates with cumulative incidence of GVHD and OS. (A) Patients (n = 438) with TNFR1 ratio more than or equal to 2.5 () experienced increased incidence of GVHD grades 2 to 4 compared with those with a ratio less than 2.5 (P < .001). Similar differences were observed when the patients were further subdivided by donor type: (B) related donor (RD; n = 267, P < .001) and (C) unrelated donor (URD; n = 171, P < .001). (D) Patients with TNFR1 ratio more than 2.5 experienced increased incidence of treatment-related mortality compared with those with a ratio of less than 2.5 (P < .001). Similar differences were observed when the patients were further subdivided by donor type: (E) RD (P = .007) and (F) URD (P = .01). (G) Patients with TNFR1 ratio more than 2.5 were more likely to die within the first year after transplantation compared with those with ratio less than 2.5 (P < .001). Similar differences were observed when the patients were further subdivided by donor type: (H) RD (P = .12) and (I) URD (P = .05).